Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years to ≤ 75 years~* Documented history of Type I or II diabetes with current treatment control (glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral medication and/or insulin~* Diagnosis of painful diabetic peripheral neuropathy in both lower extremities~* Lower extremity pain for at least 6 months~* Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain - 100 mm very severe pain)~* Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference between legs at Initial Screening~* The average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2~* The physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is ≥ 3 at Screening~* Stable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes~* If female of childbearing potential, negative urine pregnancy test at screening and using acceptable method of birth control during the study~Exclusion Criteria:~* Peripheral neuropathy caused by condition other than diabetes~* Other pain more severe than neuropathic pain~* Progressive or degenerative neurological disorder~* Myopathy~* Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease)~* Active infection~* Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)~* Positive HIV or HTLV at Screening~* Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAB), antibody to Hepatitis B antigen (IgG and IgM; HbsAb), Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening~* Subjects with known immunosuppression or currently receiving immunosuppressive drugs, chemotherapy or radiation therapy~* Stroke or myocardial infarction within last 3 months~* Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination~* Specific laboratory values at Screening including: Hemoglobin \< 8.0 g/dL, WBC \< 3,000 cells per microliter, platelet count \<75,000/mm3, Creatinine \> 2.0 mg/dL; AST and/or ALT \> 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary~* Uncontrolled hypertension as defined as sustained systolic blood pressure (SBP) \> 200 mmHg or diastolic BP (DBP) \> 110 mmHg at Screening~* Patients with a recent history (\< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings~* Subjects requiring \> 81 mg daily of acetylsalicylic acid; If ≥ 81 mg are taken at screening, subjects may be enrolled if willing/able to switch to another medication~* Use of any opioids; subjects may be enrolled if willing and able to discontinue use of these drugs 14 days prior to starting the 7 Day Daily Pain and Sleep Interference Diary and refrain from taking these drugs for the duration of the study~* Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2 inhibiting drugs, or high dose steroids (excepting inhaled steroids).Subjects may be enrolled if willing/able to undergo medication wash-out prior to the first dosing and to refrain from taking these drugs for the duration of the study;~* Major psychiatric disorder in within last 6 months~* Body mass index (BMI) \> 45 kg/m2 at Screening~* Any lower extremity amputation~* Use of an investigational drug or treatment in past 6 months~* Unable or unwilling to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose 16mg Engensis (VM202) and Placebo (Type: ACTIVE_COMPARATOR): intramuscular injections in each calf for a total of 16mg Engensis (VM202): Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
- High Dose 32mg Engensis (VM202) (Type: ACTIVE_COMPARATOR): Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
- Control - Placebo (normal saline) (Type: PLACEBO_COMPARATOR): 32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete